Publications
5808 Results
- Journal / Conference
- SITC (Nov. 6-10, Houston, TX), poster
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
Correlations Between Baseline Tumor Burden and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)
- Journal / Conference
- ISHL (October 26-28, Cologne, Germany), oral
- Year
- 2024
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)
- Journal / Conference
- ISHL (October 26-28, Cologne, Germany), oral
- Year
- 2024
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients (aged =60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826
- Journal / Conference
- San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
- Year
- 2024
- Research Committee(s)
- Breast
- Study Number(s)
- CTSU/A011202
Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial
- Journal / Conference
- San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
- Year
- 2024
- Research Committee(s)
- Breast
- Study Number(s)
- CTSU/A011401
Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial
- Journal / Conference
- San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
- Year
- 2024
- Research Committee(s)
- Breast
- Study Number(s)
- S1207
Ability to comply with placebo predicts overall survival
- Journal / Conference
- San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), rapid fire presentation (oral)
- Year
- 2024
- Research Committee(s)
- Breast
- Study Number(s)
- S0221
Long-Term Follow-up and updated analysis from S0221, Comparing Alternative Dose-Schedules of Adjuvant Anthracyclne/Taxane Therapy in High-Risk Early Breast Cancer
- Journal / Conference
- ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/EA8141
Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Younger Patients with Mantle Cell Lymphoma: Clinical Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
- Journal / Conference
- San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
- Year
- 2024
- Research Committee(s)
- Breast
- Study Number(s)
- CTSU/C40603
Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer
- Journal / Conference
- San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
- Year
- 2024
- Research Committee(s)
- Breast
- Study Number(s)
- CTSU/A011502